Aida Al-Akhdar

1 month ago | jdsupra.com | Aida Al-Akhdar |Hillary Stemple |Stephanie Trunk

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of the Inspector General (OIG), manufacturers have contested the OIG’s long-standing interpretation of the Anti-Kickback Statute (AKS).

1 month ago | afslaw.com | Stephanie Trunk |Hillary Stemple |Aida Al-Akhdar

On In a ruling issued on March 31, a federal judge upheld the OIG’s interpretation of the AKS, which formed the basis for the agency issuing an unfavorable advisory opinion to Vertex Pharmaceuticals Incorporated regarding the company’s proposed fertility assistance program. The court’s ruling is the latest blow to the pharmaceutical industry’s efforts to narrow the scope of the AKS.